Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein llb/llla in patients undergoing elective coronary angioplasty

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Coronary Artery Disease

• Publication date

  1993-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00019501-199302000-00007PMID 8269208
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile.

  1992cited by this paper
• Roles of Thrombin and Platelet Membrane Glycoprotein IIb/IIIa in Platelet‐Subendothelial Deposition After Angioplasty in an Ex Vivo Whole Artery Model

  1991cited by this paper
• Prospects for the use of antagonists to the platelet glycoprotein IIb/IIIa receptor to prevent post-angioplasty restenosis and thrombosis.

  1991cited by this paper
• Incidence and consequences of periprocedural occlusion. The 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry.

  1990cited by this paper
• Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris.

  1990cited by this paper
• Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors.

  1989cited by this paper
• Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty.

  1988cited by this paper
• Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty.

  1988cited by this paper
• Platelet accumulation in experimental angioplasty: time course and relation to vascular injury.

  1987cited by this paper
• Platelet Deposition at Angioplasty Sites and Platelet Survival Time After PTA in lliac and Femoral Arteries: Investigations with Indium-111-Oxine Labelled Platelets in Patients with ASA (1.0 g/Day)-Therapy

  1987cited by this paper
• Frequency, management and follow-up of patients with acute coronary occlusions after percutaneous transluminal coronary angioplasty.

  1987cited by this paper
• Influence of Arterial Damage and Wall Shear Rate on Platelet Deposition: Ex Vivo Study in a Swine Model

  1986cited by this paper
• In-hospital morbidity and mortality in patients undergoing elective coronary angioplasty.

  1985cited by this paper
• Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model.

  1985cited by this paper
• Inhibition of dog platelet function by in vivo infusion of F(ab')2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor.

  1985cited by this paper

• Evaluate Short-Term Outcomes of abciximab in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical Trials

  2022cites this paper
• Protein biomarkers in Parkinson's disease: Focus on cerebrospinal fluid markers and synaptic proteins

  2016cites this paper
• How abciximab might be clinically useful.

  2016cites this paper
• Glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions

  2010cites this paper
• Antithrombotic therapy for percutaneous coronary intervention.

  2006cites this paper
• Key references: Antiplatelet therapy as an adjunct to thrombolysis and coronary angioplasty

  2005cites this paper
• Platelet glycoprotein llb / llla receptor antagonists in coronary artery disease

  2005cites this paper
• The role of antiplatelet therapy in the management of acute coronary syndromes

  2005cites this paper
• GP IIb/IIIa blockade in elective percutaneous coronary intervention.

  2004cites this paper
• Abciximab During Percutaneous Coronary Intervention

  2003cites this paper
• Der Einsatz von Glykoprotein-IIb/IIIa-Rezeptor-Antagonisten bei akuten Koronarsyndromen. Teil 1: Behandlung der instabilen Angina (UA) und des Nicht-ST-Hebungsinfarktes (NSTEMI)

  2003cites this paper
• Der Einsatz von Glykoprotein-IIb/IIIa- Rezeptor-Antagonisten bei akuten Koronarsyndromen

  2003cites this paper
• Hemostasis, Thrombosis, and Vascular Biology

  2003cites this paper
• Kombination einer intraarteriellen rt-PA- plus intravenöser Abciximab-Therapie bei akuten thromboembolischen Verschlüssen der Arteria cerebri media Eine Dosisfindungsstudie

  2002cites this paper
• Expression and characterization of the ScFv fragment of antiplatelet GPIIIa monoclonal antibody SZ-21.

  2002cites this paper
• Safety, inhibition of platelet aggregation and pharmacokinetics of F(ab′) 2 fragments of the anti-glycoprotein IIb-IIIa monoclonal antibody FRaMon in high-risk coronary angioplasty

  2002cites this paper
• Drugs in development.

  2002cites this paper
• Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets.

  2002cites this paper
• In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.

  2001cites this paper
• The platelet function dose‐response to abciximab during percutaneous coronary revascularization is variable

  2001cites this paper
• Clinical trials with glycoprotein IIb/IIIa antagonists - No benefit without bleeding?

  2001cites this paper
• Monoclonal antibody therapy.

  2001cites this paper
• Platelet Aggregation Inhibition with Glycoprotein IIb–IIIa Inhibitors

  2001cites this paper
• Pharmacology of GP IIb‐IIIa Platelet Inhibitors, Part IV

  2000cites this paper
• Inhibition of vascular smooth muscle cell adhesion and migration by c7E3 Fab (abciximab): a possible mechanism for influencing restenosis.

  2000cites this paper
• Commentary on and reprint of EPIC (Evaluation of 7E3 for the Prevention of Ischemic Complications) Investigators, The, Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty, in New England Journal of Medicine (1994) 330:956–961

  2000cites this paper
• Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment.

  1999cites this paper
• Glycoprotein IIb/IIIa Receptor Antagonists

  1999cites this paper
• Thrombolyse - neue Thrombolytika, neue Begleittherapie: Update 1999

  1999cites this paper
• Development of eptifibatide.

  1999cites this paper
• Point - Counterpoint: The wide use of IIb/IIIa inhibitors in interventional cardiology - is it justified?

  1999cites this paper
• Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty.

  1999cites this paper
• Platelet glycoprotein IIB/IIIA receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention.

  1998cites this paper
• Advancing the Battle Against Acute Ischemic Syndromes: A Focus on the GP IIb‐IIIa Inhibitors

  1998cites this paper
• Restenosis, the Achilles' Heel of Coronary Angioplasty

  1998cites this paper
• The clinical impact of platelet glycoprotein IIb/IIIa receptor blockade in cardiovascular medicine.

  1998cites this paper
• New antiplatelet agents for acute coronary syndromes.

  1998cites this paper
• Pharmacodynamics and pharmacokinetics of DMP 728, a platelet GPIIb/IIIa antagonist, in healthy subjects

  1998cites this paper
• Abciximab (Reopro): a clinically effective glycoprotein IIb/IIIa receptor blocker.

  1998cites this paper
• Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis.

  1997cites this paper
• Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.

  1997cites this paper
• Abrupt vessel closure: changing importance, management, and consequences.

  1997cites this paper
• New Antiplatelet Strategies in the Adjunctive Treatment of Acute Myocardial Infarction

  1997cites this paper
• Clinical Trials of Novel Antithrombotics: Basic Concepts of Study Design and Methodology

  1997cites this paper
• [Clinical safety using the thrombocyte aggregation inhibitor c7E3 in interventional cardiology in 520 patients].

  1997cites this paper
• The Integrin α2β1 (GPIa/IIa)-I-Domain Inhibits Platelet-Collagen Interaction

  1997cites this paper
• The integrin alpha 2 beta 1 (GPIa/IIa)-I-domain inhibits platelet-collagen interaction.

  1997cites this paper
• Inhibition of Platelet Aggregation as a Surrogate Marker

  1997cites this paper
• Bleeding complications with new antithrombotics used in ischaemic heart disease.

  1996cites this paper
• Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty.

  1996cites this paper
• Immunologic Assessment of Patients Treated with Bovine Fibrin as a Hemostatic Agent

  1996cites this paper
• Role of angiographically identifiable thrombus on long-term luminal renarrowing after coronary angioplasty: a quantitative angiographic analysis.

  1996cites this paper
• Pharmacokinetics and pharmacodynamics of TP-9201, a gpIIbIIIa antagonist, administered in combination with recombinant tissue-type plasminogen activator, heparin, and aspirin in beagles.

  1996cites this paper
• The new platelet inhibitors in coronary intervention

  1996cites this paper
• The clinical role of platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease.

  1996cites this paper
• Abciximab: A New Antiaggregant Used in Angioplasty

  1996cites this paper
• Antiplatelet and anticoagulant use after myocardial infarction

  1996cites this paper
• New Antithrombotic Drugs for Coronary Artery Disease

  1996cites this paper
• Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease.

  1996cites this paper
• -Differential antithrombotic therapy in patients with low and high PTCA risk-.

  1996cites this paper
• Experimental Antileukocyte Interventions in Cerebral Ischemia

  1996cites this paper
• [Risk predictors and secondary prevention after PTCA and bypass operations].

  1995cites this paper
• Antithrombotic Therapy in Patients Undergoing Coronary Angioplasty

  1995cites this paper
• [Antiplatelet glycoprotein monoclonal antibodies: properties and practical value].

  1995cites this paper
• Thrombolytic Therapy: Future Issues

  1995cites this paper
• The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions.

  1995cites this paper
• Antithrombotic agents: from RGD to peptide mimetics.

  1995cites this paper
• Monoclonal Antibody [7E3 F(ab')2] Prevents Arterial But Not Venous Rethrombosis

  1995cites this paper
• [New aspects of blood coagulation inhibitory therapy within the scope of percutaneous transluminal coronary angioplasty (PTCA)].

  1995cites this paper
• Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine.

  1995cites this paper
• Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention.

  1995cites this paper
• Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383.

  1995cites this paper
• Pharmacokinetics and Pharmacodynamics of TP‐9201, a GPIIbIIIa Antagonist, in Rats and Dogs

  1995cites this paper
• Activation of blood coagulation by plaque rupture: mechanisms and prevention.

  1995cites this paper
• [Platelet activation and platelet aggregation in the arteriosclerotic endothelium: pathophysiological aspects and new therapeutic concepts].

  1995cites this paper
• Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators.

  1995cites this paper
• New antithrombotic drugs for systemic and local delivery for coronary artery disease.

  1995cites this paper
• Antiplatelet and antithrombotic agents

  1995cites this paper
• Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary Intervention

  1995cites this paper
• Antithrombotic therapy in patients undergoing coronary angioplasty.

  1995cites this paper
• Abciximab (c7E3 Fab)

  1994cites this paper
• New anticoagulant strategies. Current status and future potential.

  1994cites this paper
• Aktuelle Entwicklung von Thrombozytenfunktionshemmern

  1994cites this paper
• Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

  1994cites this paper
• Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

  1994cites this paper
• Chapter 11. Antithrombotic and Anti-Inflammatory Agents of The Protein C Anticoagulant Pathway

  1994cites this paper
• Platelets and vascular thrombosis.

  1994cites this paper
• Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.

  1994cites this paper
• Cyclic flow variations after coronary angioplasty in humans: clinical and angiographic characteristics and elimination with 7E3 monoclonal antiplatelet antibody.

  1994cites this paper
• The integrin αIIbβ3 as an antithrombotic target

  1994cites this paper
• Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease.

  1994cites this paper
• Use of Enzyme-Linked Immunosorbent Assay (ELISA) for Detection and Quantification of Monoclonal Antibodies

  1994cites this paper
• Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators.

  1994cites this paper
• Blood, blood components, plasma, and plasma products

  1993cites this paper
• Clinical Trials of Platelet Receptor Inhibitors

  1993cites this paper
• New Anticoagulant Strategies

  1993cites this paper
• MK‐383 (L‐700,462), a Selective Nonpeptide Platelet Glycoprotein 1Ib/IIIa Antagonist, Is Active in Man

  1993cites this paper